De-escalation approaches in the treatment of women with HER2-positive breast cancer need to be personalized, according to Carmen Criscitiello at the European Institute of Oncology. Her comments will be included in a presentation of updated research results at the inaugural ESMO Breast Cancer Congress 2019, May 2-4, in Berlin.
In last week’s issue of The Cancer Letter, the cover story featured Col. Susan Fondy, an Army veteran and stage 3 breast cancer survivor, who is now living with lymphedema. Fondy is now a lymphedema advocate, working to prevent further cuts to the already-sparse funding for the disease.
